Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study (TSAP)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
VitrOmics BV
Information provided by:
VU University Medical Center
ClinicalTrials.gov Identifier:
NCT01190241
First received: August 26, 2010
Last updated: March 19, 2014
Last verified: February 2014

August 26, 2010
March 19, 2014
August 2010
May 2014   (final data collection date for primary outcome measure)
The clinical benefit rate (CBR) of this therapy selection approach. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
The clinical benefit rate (CBR) is defined by the number of patients demonstrating either a complete or partial response or stable disease after 12 weeks of treatment.
Same as current
Complete list of historical versions of study NCT01190241 on ClinicalTrials.gov Archive Site
Not Provided
  • To compare progression free survival (PFS) using a kinase inhibitor treatment regimen selected by kinase profiling with the PFS of the most recent treatment regimen on which the patient progressed (i.e., patients are their own controls). [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • To determine the relation of Comparative Genomic Hybridization (CGH)-profiles with response to kinase inhibitors. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • To determine the relation of serum and tissue kinome proteomic and activity profiles with response to kinase inhibitors and survival. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • To correlate the frequency and phenotype of immunoregulatory cells in blood and tumor tissue with response to kinase inhibitors. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • To correlate individual pharmacodynamics with response to kinase inhibitors. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study
Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study

The purpose of this study is to select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.

Specific signalling proteins that are important for tumor growth can be targeted by agents. These are called targeted agents or targeted treatment. Thus far, it is unclear which patients will respond to these targeted agents. It is assumed that responses to these agents depend on specific receptor and protein signalling activities in tumor tissues. The investigators propose that kinase activity profiling may be a potential clinical diagnostic tool to predict tumor response to targeted treatment with tyrosine kinase inhibitors.

The investigators will determine ex vivo kinase activity inhibition profiles of tumor tissue to different targeted agents. Tumor tissue from patients with advanced cancer for whom no standard treatment is available will be used.

Patients will be treated with the selected targeted agent and the clinical benefit will be determined.

Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Advanced Solid Tumors
  • Inoperable
  • Metastasis
Drug: desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
Experimental: Targeted treatment
Targeted treatment with desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
Intervention: Drug: desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
45
Not Provided
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients presenting with an advanced (unresectable and/or metastatic) solid malignancy for whom no standard treatment is available.
  • Patients should have received at least one prior standard medical treatment regimen for their advanced disease.
  • Patients with progressive disease within 12 weeks prior to the start of study medication based on radiological assessment.
  • At least one tumor lesion should be assessable for biopsy to perform kinase activity analysis.
  • Age ≥ 18 years.
  • Histological or cytological documentation of cancer is required.
  • Patients with at least one measurable lesion. Lesions must be evaluated by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST).
  • WHO performance status 0 - 2
  • Life expectancy of at least 12 weeks
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:

    • Hemoglobin ≥ 5.6 mmol/L
    • Absolute neutrophil count (ANC) ≥ 1,500/mm3
    • Platelet count ≥ 100x10*9/l
    • Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) 22 of 59
    • ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver involvement of their cancer)
    • Serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ¡Ý 50 ml/min
    • Activated partial thromboplastin time < 1.25 x ULN
    • Prothrombin time or INR < 1.25 x ULN
  • Patients should be able to swallow oral medication.
  • Written informed consent

Exclusion Criteria:

  • History of cardiac disease:

    • Congestive heart failure >NYHA class 2.
    • Active Coronary Artery Disease (myocardial infarction more than 6 months prior to screening is allowed).
    • Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
  • Uncontrolled hypertension. Blood pressure must be ≤ 160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 3 separate measurements on at least 2 separate days.
  • Uncontrolled infections (> grade 2 NCI-CTC version 3.0).
  • Subjects with serious non-healing wound, ulcer, or bone fracture.
  • History or clinical evidence of central nervous system (CNS) disease, including primary brain tumor and brain metastases.
  • Clinical findings associated, in the judgment of the investigator, with an unacceptably high tumor biopsy risk
  • Pregnant or breast-feeding subjects.
  • Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy during the study or within 4 weeks of the start of study drug.
  • Radiotherapy on target lesions during study or within 4 weeks of the start of study drug. Palliative radiotherapy will be allowed.
  • Concomitant use of dexamethasone, anti-convulsants and anti-arrhythmic drugs other than digoxin or beta blockers.
  • Major surgery within 28 days of start of treatment. The surgical wound should be fully healed prior to the start of study drug. In subjects who experienced wound healing complications during therapy, treatment should be withheld until the wound is fully healed.
  • Substance abuse, medical, psychological or social conditions that may interfere with the subject¡-s participation in the study or evaluation of the study results.
  • Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01190241
2010/124
No
H.M.W. Verheul, MD, PhD, Professor of Medical Oncology, VU University Medical Center
VU University Medical Center
VitrOmics BV
Principal Investigator: Henk Verheul, M.D., PhD VU University Medical Center
VU University Medical Center
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP